First Horizon Advisors Inc. reduced its position in Merck & Co., Inc. by 8.7%, selling 15,566 shares in the 4th quarter, ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price in January. But this ...

(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...

Merck (MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...

The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

If you suffered losses exceeding $100,000 in Merck between February 3, 2022 and February 3, 2025 and would like to discuss ...

Merck & Co. is facing a class action lawsuit over Gardasil sales projections. Learn how to recover losses with Levi & ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.

Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...